STAT

Opinion: Don’t let the opioid settlement fritter away funds like the tobacco settlement did

Money from any forthcoming opioid settlement must be applied to help victims of opioid and other substance use disorders through access to evidence-based care, research, and training.
Twenty years after the landmark tobacco settlement, only 2.6% of the funds had been spent on smoking prevention and cessation programs.

In response to the opioid epidemic in the U.S., cities, counties, states, insurers, and medical groups filed more than 2,000 lawsuits seeking to hold pharmaceutical companies accountable for it. A tentative settlement is now on the horizon: according to news reports on Wednesday, Purdue Pharma will pay up to $12 billion over time and the Sackler family, which owns the company, will give up control of it.

Opinions abound on how this money should be spent.

In the midst of this discussion, as a result of opioid overdoses.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

Related Books & Audiobooks